Forecast Of The Day: Boston Scientific Revenue From Cardiac Rhythm Management

+26.99%
Upside
40.15
Market
50.99
Trefis
BSX: Boston Scientific logo
BSX
Boston Scientific

What? 

Boston Scientific (NYSE:BSX) Revenue from Cardiac Rhythm Management declined from around $1.9 billion in 2019 to around $1.7 billion in 2020. Trefis expects the metric to recover to about $2 billion in 2021 and $2.05 billion in 2022.

Why?

Relevant Articles
  1. What To Expect From Boston Scientific Stock Following Q1 Earnings?
  2. This Software Company Is Likely To Offer Better Returns Over Boston Scientific Stock
  3. Company Of The Day: Boston Scientific
  4. Is Boston Scientific Stock A Good Buy At $43?
  5. What To Expect From Boston Scientific Stock Following Q4 Earnings?
  6. Should You Buy Boston Scientific Stock Over Its Industry Peer?

While sales fell in 2020 due to the Covid-19 pandemic and the related decline in elective procedures, we expect sales to rebound in 2021 as Covid-19 vaccination rates improve. We expect longer-term growth to be driven by new product launches as well as expansion in emerging markets.

So What?

We don’t think the projected post-Covid recovery in Boston Scientific’s business is priced into its stock yet. We value BSX at about $50 per share, a premium of 12% over the current market price.

See Our Complete Analysis For BSX

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates